Featured Post from Aston University

Aston University researchers collaborate with biotechnology start-up to develop drugs to tackle irreversible lung disease

Jan 23, 2023

3 min



• Researchers in the School of Biosciences partner with preclinical-stage biotechnology start-up company to develop drugs for fibrotic diseases

• Professor Martin Griffin and team develop TG2 inhibitors to help treat a serious chronic lung disease called idiopathic pulmonary fibrosis.

• Isterian Biotech is part of Cambrian BioPharma who have been working with Aston University since 2019.


Aston University scientists are working with start-up company, Isterian Biotech, part of Cambrian BioPharma, to develop novel drugs to treat fibrotic diseases such as lung disease.


The focus of preclinical-stage biotechnology company Isterian Biotech is on developing novel drugs to stop or reverse the pathological accumulation of crosslinked proteins commonly observed in all major organs with age.


As we age a chronic increase of crosslinked proteins occurs in the extracellular matrix (ECM), that surround, support, and give structure to the cells and tissues in the body. These crosslinked proteins are difficult for the body to degrade and over time can make organs stiff and dysfunctional, ultimately resulting in fibrosis. Reversing the accumulation of these pathological crosslinks will greatly contribute to reducing fibrosis.


The start-up is working to develop small molecule inhibitors of transglutaminase 2 also known as TG2, which is one of the major crosslinking enzymes in the human body, that becomes more active during ageing - thus resulting in fibrotic diseases such as a type of lung disease known as idiopathic pulmonary fibrosis (IPF).


Isterian President and Chairman of the Board, Georg C Terstappen, PhD said:


"Isterian's strategy of combining rational drug design with efficient multiparametric profiling of synthesized small molecules has been both impressive and highly productive. Notably, for one of our highly potent and selective TG2 inhibitors, we have recently demonstrated efficacy in a mouse model of lung fibrosis for the first time.

"Using this state-of-the-art approach to drug discovery combined with an impressive team gives us great confidence in the future of this novel company."


IPF is a progressive, irreversible disease that is characterized by pathological crosslinking of extracellular matrix (ECM) proteins (a large network of proteins and other molecules that surround, support, and give structure to the cells and tissues in the body) leading to excessive deposition of collagen. This means that in IPF scar tissue or fibrosis builds up around the air sacs (alveoli) in the lungs and reduces the ability to transfer oxygen that is breathed into the blood, resulting in severe restriction of lung capacity and function.


IPF is the most common form of pulmonary fibrosis. The disease affects between 200,000 and 300,000 people globally. Statistics from the charity Action for Pulmonary Fibrosis suggest there are about 30,000 people living with IPF in the UK with an estimated 6,000 new cases of the condition each year. The disease usually develops in people aged 70 and older and is more common in men. But it can occur in younger individuals, particularly if there is a family history of idiopathic pulmonary fibrosis.


The company was founded by capitalizing on over 35 years of scientific research from the laboratory of Professor Martin Griffin and his team Dr Dan Rathbone and Dr Vivian Wang at Aston University.


Their work with small molecule inhibitors selective for TG2 has demonstrated reduction of fibrosis in multiple organs in a number of animal models. In 2019, Aston University partnered with Cambrian to form Isterian Biotech with a mission to develop safe and effective TG2 inhibitors to treat Idiopathic pulmonary fibrosis (IPF), a devastating fibrotic disease of the lung.


Professor Martin Griffin, Biosciences Research Group, Aston University said: “We are delighted to continue our work with Isterian researching how we can further develop TG2 inhibitors to help tackle this awful disease.”


CEO of Cambrian BioPharma, James Peyer, commented: "As Cambrian continues on its mission to build medicines that will redefine healthcare in the 21st century, we are very thankful to find brilliant scientists such as Martin and his team that are willing to break the mold. Isterian and its work to reduce fibrosis are a perfect fit alongside the other pipeline companies our team has announced in 2022."


The company's current pipeline includes an advanced preclinical-stage TG2 inhibitor for inhaled administration and several structurally unrelated back-up compounds for the treatment of IPF.


For more information about the School of Biosciences at Aston University, please visit our website.



You might also like...

Check out some other posts from Aston University

2 min

Aston University researcher investigates safety risks of secondhand cosmetics sold online

As second-hand beauty products grow in popularity, so do questions about their safety. At Aston University, Dr Amreen Bashir, senior lecturer in biomedical science, is leading an academic investigation into the microbiological risks associated with pre-owned cosmetics being sold through online platforms like Vinted and Facebook Marketplace. The project, which has received ethical approval from the University’s Health and Life Sciences Ethics Committee, will assess the types of bacteria and potential contaminants found in used cosmetics – such as makeup and skincare – when they are resold and reused by new owners.  “Second-hand beauty is trending for sustainability and affordability,” said Dr Bashir. “But very little research has explored what’s actually living in those products — and what kind of risk that might pose to everyday users.” Why this matters Pre-owned beauty items are often marketed as sustainable and cost-effective, but without careful handling they can harbour microorganisms – from bacteria to mould – that may cause infections, allergic reactions, or worse. Without knowing when a product was first opened or its expiry date, buyers could be unknowingly using unsafe cosmetics. Dr Bashir’s study will be among the first in the UK to analyse not just contamination, but also expiry timelines, and how low consumer awareness of these dates adds to the risk. The study will explore: • Types of microbiological contamination found in used products • Risks posed by product type (e.g., mascaras vs. powders) • Storage conditions and packaging integrity • Expiry dates and consumer awareness, for example: - Cosmetics have expiry timelines printed as either a date or a small jar symbol with a number (e.g., 6M, 12M, 24M, 36M), indicating months after opening. - Products can be contaminated long before the expiry date if not stored properly. - Dr Bashir’s previous research found that many makeup users didn’t know where to find the expiry date on the packaging and often kept products for years past their safe-use period. Potential to shape consumer safety and regulation With second-hand beauty sales on the rise, the findings could help shape public health messaging, consumer awareness campaigns, and online marketplace guidelines. Results could also support industry discussions on product labelling, returns, and hygiene standards. The project bridges the gap between digital consumer behaviour and health science, with implications for how individuals make purchasing decisions and how regulations adapt to a fast-changing beauty market. ⸻ Want to learn more or collaborate? Updates will be shared through academic publications and public-facing channels once data collection and sample testing are complete. Click on the icon below to connect with: Dr Amreen Bashir, senior lecturer in biomedical sciences Areas of expertise: Clinical microbiology, antimicrobial resistance, bacteria found in food, makeup products, food and water microbiology

3 min

Unexpected A-Level results? Here’s advice from a psychologist

On 14 August young people across England, Northern Ireland and Wales will receive their A Level results. Many will receive the grades they hoped for however those who receive results that aren’t as expected, either worse or better, there is the option of entering Clearing, the period when universities advertise remaining places on undergraduate courses Aston University is offering guidance to help secure a place on a degree course and those who already have their results can enter Clearing from 5 August. There is more information about the process on the Aston University website at https://www.aston.ac.uk/clearing/guide Going through the process of waiting for and receiving A Level results can be overwhelming Dr Natalia Stanulewicz-Buckley is a social health psychologist and is a lecturer in the School of Psychology and Aston Medical School at Aston University. She has the following advice for anyone who doesn’t get the grades for which they hoped: “What if your A-level results are not what you hoped for? Breathe. Feel. Regroup. The path ahead still holds endless possibilities. “As people get older and gain more life experience, they often realise that what once seemed like a humongous failure or disappointment, with time, bears a lighter load. So, what advice would I share with young people facing A-level results that may not have aligned with their expectations and hopes, and who might be facing Clearing or having to consider other options? “First of all, take a few long inhales and even longer exhales (for 3-4 minutes). This kind of breathing exercise can help you feel calmer when facing a stressful situation. “Next, acknowledge your feelings. It’s okay to feel disappointed, disheartened, or even angry when life doesn’t go according to plan. These emotions show that this outcome matters deeply to you. But they don’t mean that all is lost. “Take time to sit with your emotions and try to share your concerns with people who might be going through a similar experience, or with those you trust to support you - friends, siblings, family members, or teachers. There is truth in the saying, ‘A problem shared is a problem halved.’ “Once you've made space for your emotions and worked through them - remember, emotions are like waves; they arise, reach a peak, and then subside - you might feel more ready to consider your options. Believe me, there will be many, Clearing, taking a year out to travel or volunteer, doing an internship, and more. “Ask yourself, 'What path is most aligned with my plans and ambitions for the future?' Follow that answer. And who knows - perhaps in time, you’ll look back on this stressful moment and the decisions you made in response to it and realise that having to re-adjust your university plans was the best thing that could have happened. “As the saying goes, ‘When one door closes, another one opens.’ But most importantly, please be kind to yourself. Treat yourself as you would a close friend—with understanding, support, and compassion. It may be reassuring to remember that you did the best you could in the situation you were in, with the resources you had. That is all anyone could ever ask of you.” To interview Dr Stanulewicz-Buckley or for other media enquiries contact Nicola Jones, Press and Communications Manager, on (+44) 7825 342091 or email: n.jones6@aston.ac.uk To find out more about Dr Stanulewicz-Buckley’s work visit https://research.aston.ac.uk/en/persons/natalia-stanulewicz-buckley Courses available through clearing at Aston University can be viewed at https://www.aston.ac.uk/clearing/vacancies and anyone who is waiting for their results can register for Priority Clearing at https://www.aston.ac.uk/clearing#register to receive vacancy alerts, advice and tips. From 8am Thursday 14 August there will be three easy ways to apply for courses at Aston University through Clearing, either call 0800 917 5923 to speak with an adviser, submit a Clearing application form at https://www.aston.ac.uk/clearing/guide or use the online live chat service. Finally, students can message on Instagram at https://www.instagram.com/AstonUniversity/

3 min

First AI-powered Smart Care Home system to improve quality of residential care

Partnership between Lee Mount Healthcare and Aston University will develop and integrate a bespoke AI system into a care home setting to elevate the quality of care for residents By automating administrative tasks and monitoring health metrics in real time, the smart system will support decision making and empower care workers to focus more on people The project will position Lee Mount Healthcare as a pioneer of AI in the care sector and opening the door for more care homes to embrace technology. Aston University is partnering with dementia care provider Lee Mount Healthcare to create the first ‘Smart Care Home’ system incorporating artificial intelligence. The project will use machine learning to develop an intelligent system that can automate routine tasks and compliance reporting. It will also draw on multiple sources of resident data – including health metrics, care needs and personal preferences – to inform high-quality care decisions, create individualised care plans and provide easy access to updates for residents’ next of kin. There are nearly 17,000 care homes in the UK looking after just under half a million residents, and these numbers are expected to rise in the next two decades. Over half of social care providers still retain manual and paper-based approaches to care management, offering significant opportunity to harness the benefits of AI to enhance efficiency and care quality. The Smart Care Home system will allow for better care to be provided at lower cost, freeing up staff from administrative tasks so they can spend more time with residents. Manjinder Boo Dhiman, director of Lee Mount Healthcare, said: “As a company, we’ve always focused on innovation and breaking barriers, and this KTP builds on many years of progress towards digitisation. We hope by taking the next step into AI, we’ll also help to improve the image of the care sector and overcome stereotypes, to show that we are forward thinking and can attract the best talent.” Dr Roberto Alamino, lecturer in Applied AI & Robotics with the School of Computer Science and Digital Technologies at Aston University said: “The challenges of this KTP are both technical and human in nature. For practical applications of machine learning, it’s important to establish a common language between us as researchers and the users of the technology we are developing. We need to fully understand the problems they face so we can find feasible, practical solutions. For specialist AI expertise to develop the smart system, LMH is partnering with the Aston Centre for Artificial Intelligence Research and Application (ACAIRA) at Aston University, of which Dr Alamino is a member. ACAIRA is recognised internationally for high-quality research and teaching in computer science and artificial intelligence (AI) and is part of the College of Engineering and Physical Sciences. The Centre’s aim is to develop AI-based solutions to address critical social, health, and environmental challenges, delivering transformational change with industry partners at regional, national and international levels. The project is a Knowledge Transfer Partnership. (KTP). Funded by Innovate UK, KTPs are collaborations between a business, a university and a highly qualified research associate. The UK-wide programme helps businesses to improve their competitiveness and productivity through the better use of knowledge, technology and skills. Aston University is a sector leading KTP provider, ranked first for project quality, and joint first for the volume of active projects. For more information on the KTP visit the webpage.

View all posts
Powered by